SPIA
CRVS icon

Steward Partners Investment Advisory’s Corvus Pharmaceuticals CRVS Stock Holding History

Steward Partners Investment Advisory’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-25
Closed – – 3383
2022
Q3 		$0 Hold
25
– – ﹤0.01% 3251
2022
Q2 		$0 Hold
25
– – ﹤0.01% 3261
2022
Q1 		$0 Hold
25
– – ﹤0.01% 3300
2021
Q4 		$0 Hold
25
– – ﹤0.01% 3201
2021
Q3 		$0 Buy
+25
New +$74 ﹤0.01% 3200

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Steward Partners Investment Advisory's CRVS Position: Q4 2022 in Review

Steward Partners Investment Advisory sold out of Corvus Pharmaceuticals (CRVS) in Q4 2022, closing a stake of 25 shares.

Steward Partners Investment Advisory first reported a position in CRVS in Q3 2021 and held it in 5 quarters. The position peaked at $0 in Q3 2022. 42 funds tracked by Wall St. Rank hold CRVS as of Q4 2022.

  • Steward Partners Investment Advisory reported no remaining Corvus Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 25 Corvus Pharmaceuticals shares in Q4 2022.
  • Steward Partners Investment Advisory first reported a position in Corvus Pharmaceuticals in Q3 2021 and held it in 5 quarters.
  • Steward Partners Investment Advisory's Corvus Pharmaceuticals position peaked at $0 in Q3 2022.
  • 42 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2022.

Based on Steward Partners Investment Advisory's 13F filing for Q4 2022, filed 15 Feb 2023.